Two New Reviews Rate the BPC-157 Evidence: Three Small Human Studies, Very Low Certainty

Evidence reviews, not trials. Neither paper tests BPC-157. Each summarizes what other studies have reported and rates its quality. BPC-157 is an unapproved research compound, and the conclusions below are the reviewers’, quoted or paraphrased from their abstracts, which were the parts of the papers available for this article.

The human evidence: Acta Orthopaedica Belgica

The review, published October 8, 2026, is PRISMA-compliant and prospectively registered with PROSPERO (CRD420261406325). The authors searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to June 1, 2026 for any human study of BPC-157, describing it as a synthetic pentadecapeptide popular among athletes for injury recovery despite lacking regulatory approval for human use.

Three studies, 30 participants in all, met the criteria: a retrospective study of intra-articular injections for knee pain (n=16), a retrospective pilot study of intravesical use for interstitial cystitis (n=12), and a prospective pilot study of intravenous safety (n=2). All three reported symptom improvement in most participants and no treatment-related adverse events. The authors judged all three to be of poor methodological quality, rated the overall certainty of evidence as very low (serious risk of bias, indirectness and imprecision), and concluded that BPC-157 “should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.”

Two details matter for reading those results. The reviewers describe the three studies as retrospective or pilot studies, and none is a randomized, controlled trial. And the reviewers’ poor-quality judgment covers the reported absence of adverse events as well as the reported improvement, in a total of 30 participants.

The animal evidence: the International Journal of Molecular Sciences

The critical review, published September 19, 2026, assessed the preclinical evidence for BPC-157 in rodent ischemia-reperfusion injury and related reperfusion-associated vascular injury models, with searches up to June 24, 2026. It did not perform a meta-analysis because of heterogeneity in organs, injury models, doses, routes, timing and outcomes.

Across the rodent studies, the review reports that BPC-157 administration has been associated with reduced oxidative injury, modulation of nitric-oxide-related vascular responses, lower inflammatory and apoptotic markers, and changes in VEGF/VEGFR2-Akt-eNOS signaling, with organ-specific findings in skeletal muscle, hippocampus, intestine and liver models. It also states that the evidence base is heterogeneous and “frequently relies on short observation periods, single-dose paradigms, and incompletely characterized risk-of-bias domains.” Its conclusion is that the evidence supports BPC-157 as a “hypothesis-generating investigational candidate for further preclinical IRI research rather than as an established therapy.” It calls for independent blinded replication.

What the two reviews have in common

Read together, the reviews describe a compound with a sizeable animal literature that the reviewers consider hard to interpret, and a human literature too small and too weak to support clinical conclusions. The Acta Orthopaedica Belgica reviewers advise against clinical use outside regulated trials, and the IJMS review calls for independent replication. Prof. Peptide’s regulatory background on peptide compounding is in Peptides Loosen, GLP-1 Compounding Tightens, and the compound’s own profile at BPC-157.

What this is, and isn’t

This is a report on two evidence reviews, read from their abstracts. It is not a systematic review by Prof. Peptide and not an evaluation of any product or seller. It does not say that BPC-157 works, or that it is safe or unsafe in people. BPC-157 is not approved for human use. Nothing here is medical advice, a dosing recommendation or a usage recommendation.

Sources

• Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, Oct. 8, 2026 (PubMed record and abstract) — primary: the three-study finding, quality rating and conclusion. DOI 10.52628/92.3.15837; PROSPERO CRD420261406325.
• BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci, Sept. 19, 2026 (PubMed record and abstract) — primary: the rodent-evidence summary and conclusion. DOI 10.3390/ijms27188344.